PL1711473T3 - Podstawione N-cykloheksyloimidazolinony o działaniu MCH-modulatorowym - Google Patents

Podstawione N-cykloheksyloimidazolinony o działaniu MCH-modulatorowym

Info

Publication number
PL1711473T3
PL1711473T3 PL05707002T PL05707002T PL1711473T3 PL 1711473 T3 PL1711473 T3 PL 1711473T3 PL 05707002 T PL05707002 T PL 05707002T PL 05707002 T PL05707002 T PL 05707002T PL 1711473 T3 PL1711473 T3 PL 1711473T3
Authority
PL
Poland
Prior art keywords
cyclohexylimidazolinones
mch
substituted
modulatory effect
modulatory
Prior art date
Application number
PL05707002T
Other languages
English (en)
Inventor
Lothar Schwink
Thomas Boehme
Matthias Gossel
Siegfried Stengelin
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PL1711473T3 publication Critical patent/PL1711473T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05707002T 2004-01-25 2005-01-25 Podstawione N-cykloheksyloimidazolinony o działaniu MCH-modulatorowym PL1711473T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004003811A DE102004003811A1 (de) 2004-01-25 2004-01-25 Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2005/000700 WO2005070898A1 (de) 2004-01-25 2005-01-25 Substituierte n-cyclohexylimidazolinone mit mch-modulatorischer wirkung
EP05707002A EP1711473B1 (de) 2004-01-25 2005-01-25 Substituierte n-cyclohexylimidazolinone mit mch-modulatorischer wirkung

Publications (1)

Publication Number Publication Date
PL1711473T3 true PL1711473T3 (pl) 2008-05-30

Family

ID=34745115

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05707002T PL1711473T3 (pl) 2004-01-25 2005-01-25 Podstawione N-cykloheksyloimidazolinony o działaniu MCH-modulatorowym

Country Status (26)

Country Link
EP (1) EP1711473B1 (pl)
JP (1) JP2007518771A (pl)
KR (1) KR20060128955A (pl)
CN (1) CN1934090B (pl)
AR (1) AR047453A1 (pl)
AT (1) ATE383342T1 (pl)
AU (1) AU2005206308A1 (pl)
BR (1) BRPI0507104A (pl)
CA (1) CA2554233A1 (pl)
CY (1) CY1107429T1 (pl)
DE (2) DE102004003811A1 (pl)
DK (1) DK1711473T3 (pl)
ES (1) ES2297667T3 (pl)
HR (1) HRP20080077T3 (pl)
IL (1) IL176917A0 (pl)
MA (1) MA28345A1 (pl)
MY (1) MY139107A (pl)
NO (1) NO20063757L (pl)
PE (1) PE20051091A1 (pl)
PL (1) PL1711473T3 (pl)
PT (1) PT1711473E (pl)
RS (1) RS50543B (pl)
RU (1) RU2006130626A (pl)
TW (1) TW200604182A (pl)
UY (1) UY28726A1 (pl)
WO (1) WO2005070898A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412007T3 (es) 2005-12-21 2013-07-09 Janssen Pharmaceutica, N.V. Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
ES2483866T3 (es) 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
KR100893394B1 (ko) * 2007-05-11 2009-04-17 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
DE102008060967A1 (de) * 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
PL223830B1 (pl) 2012-04-03 2016-11-30 Univ Jagiellonski Pochodne aromatycznych imidazolidynonów i ich zastosowanie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348328B2 (en) * 2001-12-04 2008-03-25 Schering Corporation MCH antagonists for the treatment of obesity
DE10233817A1 (de) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CN1934090B (zh) 2010-04-07
DK1711473T3 (da) 2008-05-26
RS50543B (sr) 2010-05-07
MY139107A (en) 2009-08-28
MA28345A1 (fr) 2006-12-01
TW200604182A (en) 2006-02-01
DE102004003811A1 (de) 2005-08-11
PT1711473E (pt) 2008-03-07
DE502005002497D1 (de) 2008-02-21
NO20063757L (no) 2006-10-11
UY28726A1 (es) 2005-08-31
AR047453A1 (es) 2006-01-18
JP2007518771A (ja) 2007-07-12
ATE383342T1 (de) 2008-01-15
AU2005206308A1 (en) 2005-08-04
EP1711473A1 (de) 2006-10-18
IL176917A0 (en) 2006-12-10
PE20051091A1 (es) 2006-01-23
KR20060128955A (ko) 2006-12-14
WO2005070898A1 (de) 2005-08-04
CN1934090A (zh) 2007-03-21
CA2554233A1 (en) 2005-08-04
RU2006130626A (ru) 2008-02-27
BRPI0507104A (pt) 2007-06-19
HRP20080077T3 (en) 2008-03-31
EP1711473B1 (de) 2008-01-09
CY1107429T1 (el) 2012-12-19
ES2297667T3 (es) 2008-05-01

Similar Documents

Publication Publication Date Title
EG23651A (en) Culturama
DE602005010905D1 (en) Roboterhandvorrichtung
DE502005007040D1 (en) Laryngoskop
PT1711473E (pt) N-ciclo-hexilimidazolinonas substituídas com acção moduladora de mch
DE602005008719D1 (en) Notinformationsschild
EP1732560A4 (en) SUBSTITUTED CINNOLINE-4-YLAMINE
IL180888A0 (en) Substituted n-acyl-2-aminothiazoles
DE502004004685D1 (en) Giessmaschine
GB0406443D0 (en) Cast-cutter
DE502004004917D1 (en) Multiaxialkomplex
GB0409310D0 (en) Cancap
GB0413160D0 (en) Autopark
ZA200700723B (en) Substituted N-acyl-2-aminothiazoles
GB0410629D0 (en) Dry-bye
DE502005006813D1 (en) Common-rail-injektor
DE502005004945D1 (en) Auto-splice-system
SI1711473T1 (sl) Substituirani N-cikloheksilimidazolinoni z MCH-modulatornim ucinkom
GB0423060D0 (en) Hedgefence
GB0419025D0 (en) Boardgame
GB0426787D0 (en) Vessel-filling arrangements
AU302217S (en) Bedhead
GB0424176D0 (en) Equilight
GB0416777D0 (en) Tooth-x
GB0414980D0 (en) Hydroskimmer
GB0422924D0 (en) Fusion-insitu